Neuland Labs Launches App at Informex Allowing Customers 24/7 Access to GuarD Project Management System for On-Time Production

HYDERABAD, India and NEW ORLEANS, Feb. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will launch a mobile app version of its GuarD project management system at the Informex USA 2012 conference.  

Saharsh R. Davuluri, President of Contract Research at Neuland, will officially launch the GuarD project management app at an Informex 2012 press briefing at 11:00 am CT on February 15, 2012 in Room 240 at the Morial Convention Center in New Orleans. 

Mr. Davuluri notes, "Our GuarD system is a powerful collaborative tool that has helped increase Neuland's record of on-time production by identifying critical subtasks and enabling team leaders and customers to monitor and track progress at every stage in real-time.  We are now pleased to launch our new mobile phone app that allows our customers and team members to access the capabilities of the GuarD system at anytime and anywhere."

GuarD was developed by Neuland Labs to support the company's goal of making its manufacturing process completely transparent and an extension of its customers' resources, while providing them the opportunity to participate fully in project planning and real-time tracking.  GuarD uses the principles of Critical Chain Project Management, which emphasizes resource availability and flexibility to maintain project timelines, rather than requiring rigid scheduling. 

In concert with the customer, the Neuland project team creates a detailed project plan that is viewable in an online template.  GuarD allows the team to keep customers completely up to date on the progress of their projects, providing critical information on the latest task updates, expected time of task completion and potential challenges.  A key advantage of the GuarD system is that its detail and interactive nature make it easy to identify and manage delays at any step in the process.  Customers are invited to contribute to solutions based on their experience and priorities.

Working closely with customers has been an important commitment of Neuland's from the beginning.  Yet as Mr. Davuluri notes, "Implementing GuarD represented a major step forward in our ability to bring our customers into the project management process as full participants.  We are now proud to introduce our next advance in customer participation by using 21st century communications technology to provide around-the-clock access to the GuarD system."

Neuland experts also are presenting several talks at Informex 2012:

• Dr. Ponnaiah Ravi, Senior Vice President of R&D at Neuland Laboratories Ltd., will present a TechTalk on Selection Methods for Managing Genotoxic Impurities in APIs at 3:30 pm CT on February 15, 2012 at the Elsevier TechTalks booth #950. 
• Thomas Speace, President and CEO of Neuland Laboratories Inc., will speak on Life Cycle Management at an Informex Breakfast Briefing at 7:30 am CT on February 16, 2012 in Room 260.

Neuland scientists will be available throughout the conference to provide free project consultations.  Appointments can be scheduled at Neuland booth #2114.  Neuland will also be giving away a free Apple iPad 2—visit the booth for more details.

Informex USA is the premier annual tradeshow for the fine, specialty and custom chemical industries, bringing together motivated buyers and sellers of chemicals, chemical technologies, and related services.  It is being held at the Morial Convention Center in New Orleans, LA, February 14-17, 2012.  For more information, visit http://www.informex.com/informex-usa.

About Neuland Labs                                                                                                                                         

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  The company is committed to research, supporting a state-of-the-art R&D operation.  Neuland Labs scientists have developed more than 300 processes from bench scale to commercial production and filed more than 400 drug master files worldwide.  Its manufacturing facilities are inspected and approved by the FDA and other leading regulatory agencies.  Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001.  Neuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO. For more information, visit http://neulandlabs.com.

Neuland Laboratories Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an offer on a rights basis of its equity shares and has filed a draft letter of offer with the Securities and Exchange Board of India ("SEBI"), which is available on the website of SEBI at www.sebi.gov.in and the website of the Lead Manager at www.sbicaps.com.

SOURCE Neuland Laboratories Ltd.